Balance Sheet (Annual)

ENV / Envestnet, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 64,909 29,983 49,942 209,754 51,718 52,592 60,115
    Accounts Receivable Net Current 9,644 9,188 19,848 20,345 46,756 44,268 51,522
    Prepaid Expense And Other Assets Current 4,040 2,501 7,155 7,242 15,175 16,224 19,470
    Assets Current 78,785 43,761 79,407 241,995 113,649 113,084 131,107
  Property Plant And Equipment Net 11,091 11,791 12,766 16,629 28,681 33,000 35,909
  Capitalized Computer Software Net 3,524 4,324 5,740 7,023 9,897 14,860 22,174
  Finite Lived Intangible Assets Net - 27,150 35,698 58,654 292,675 265,558 222,731
  Goodwill 22,223 65,644 74,335 104,976 421,273 431,936 432,955
  Other Assets Noncurrent 3,162 3,535 4,929 9,516 16,702 13,963 17,176
  Assets 137,702 162,399 221,242 439,358 885,565 872,401 862,052
Liabilities And Stockholders Equity
  Liabilities Current
    Accrued Liabilities And Other Liabilities - - - - - - 105,897
    Accounts Payable Current 1,974 2,614 5,528 4,869 10,420 11,480 11,097
    Business Combination Contingent Consideration Liability Current - - 6,008 6,405 2,537 2,286 2,115
    Contract With Customer Liability Current - - - - - - -
    Liabilities Current 17,143 28,583 53,023 64,680 111,457 155,954 140,355
  Convertible Debt Noncurrent - - - - 150,133 152,575 158,990
  Line Of Credit - - - - - - 81,168
  Business Combination Contingent Consideration Liability Noncurrent - - 11,297 7,462 1,506 2,582 666
  Contract With Customer Liability Noncurrent - - - - - - -
  Deferred Rent Credit Noncurrent 1,414 2,195 2,051 3,588 5,548 12,060 15,185
  Deferred Tax Liabilities Noncurrent - - - - - 5,555 969
  Other Liabilities Noncurrent 573 1,739 2,404 2,430 6,288 13,436 15,102
  Liabilities 22,063 36,403 73,470 235,867 444,738 458,214 424,482
  Commitments And Contingencies - - - - - - -
  Redeemable Noncontrolling Interest Equity Carrying Amount - - - 1,500 900 900 900
  Stockholders Equity Including Portion Attributable To Noncontrolling Interest
    Stockholders Equity
      Preferred Stock Value - - - - - - -
      Common Stock Value 218 220 228 232 270 278 287
      Additional Paid In Capital 163,584 173,611 192,341 233,888 474,726 516,675 556,257
      Retained Earnings Accumulated Deficit -37,742 -37,277 -33,617 -19,443 -15,007 -70,574 -73,854
      Treasury Stock Value 10,421 10,558 11,180 13,242 20,654 33,068 47,042
      Accumulated Other Comprehensive Income Loss Net Of Tax - - - - 194 -422 624
      Stockholders Equity 115,639 125,996 147,772 201,435 439,529 412,889 436,272
  Minority Interest - - - 556 398 398 398
  Stockholders Equity Including Portion Attributable To Noncontrolling Interest - - - 201,991 439,927 413,287 436,670
  Liabilities And Stockholders Equity 137,702 162,399 221,242 439,358 885,565 872,401 862,052

Peers - Business Services, Not Elsewhere Classified (7389)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 29404K106